2022-03-08 |
2022-03-04 |
V
Vente
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Dirigeant
|
6 710
-17.2%
30,56
205 058
USD
|
6 710
-17.2%
|
30,56
|
205 058
USD
|
|
2022-03-08 |
2022-03-04 |
V
Vente
|
PIMSTONE SIMON N.
Administrateur non-exécutif
|
4 793
-2.2%
30,56
146 474
USD
|
4 793
-2.2%
|
30,56
|
146 474
USD
|
|
2022-03-08 |
2022-03-04 |
V
Vente
|
PIMSTONE SIMON N.
Administrateur non-exécutif
|
4 532
-2.1%
30,66
138 951
USD
|
4 532
-2.1%
|
30,66
|
138 951
USD
|
|
2022-01-21 |
2022-01-21 |
A
Achat
|
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Dirigeant
|
700
+inf%
28,81
20 167
USD
|
700
+inf%
|
28,81
|
20 167
USD
|
|
2021-12-07 |
2021-12-06 |
A
Achat
|
Von Seggern Christopher
Chief Commercial Officer
Dirigeant
|
4 000
+inf%
24,40
97 600
USD
|
4 000
+inf%
|
24,40
|
97 600
USD
|
|
2021-11-16 |
2021-11-15 |
V
Vente
|
PIMSTONE SIMON N.
Administrateur non-exécutif
|
17 557
-7.7%
31,33
550 061
USD
|
17 557
-7.7%
|
31,33
|
550 061
USD
|
|
2021-06-01 |
2021-05-28 |
V
Vente
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Dirigeant
|
2 912
-8.3%
18,81
54 775
USD
|
2 912
-8.3%
|
18,81
|
54 775
USD
|
|
2021-06-01 |
2021-05-28 |
V
Vente
|
ROBIN SHERRINGTON
EVP, Strategy & Innovation
Dirigeant
|
3 155
-8.2%
18,81
59 346
USD
|
3 155
-8.2%
|
18,81
|
59 346
USD
|
|
2021-06-01 |
2021-05-27 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
8 485
-5.6%
18,68
158 500
USD
|
8 485
-5.6%
|
18,68
|
158 500
USD
|
|
2021-06-01 |
2021-05-27 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
2 579
-1.7%
18,69
48 202
USD
|
2 579
-1.7%
|
18,69
|
48 202
USD
|
|
2020-06-02 |
2020-06-01 |
V
Vente
|
PIMSTONE SIMON N.
CEO
Administrateur exécutif
|
3 000
-1.2%
14,43
43 290
USD
|
3 000
-1.2%
|
14,43
|
43 290
USD
|
|
2020-06-02 |
2020-05-29 |
V
Vente
|
PIMSTONE SIMON N.
CEO
Administrateur exécutif
|
5 000
-1.9%
13,99
69 950
USD
|
5 000
-1.9%
|
13,99
|
69 950
USD
|
|
2019-09-24 |
2019-09-20 |
V
Vente
|
PIMSTONE SIMON N.
CEO
Administrateur exécutif
|
10 395
-3.9%
9,51
98 856
USD
|
10 395
-3.9%
|
9,51
|
98 856
USD
|
|
2019-09-20 |
2019-09-20 |
V
Vente
|
HOLLER FRANK A
|
5 206
-4.2%
9,39
48 884
USD
|
5 206
-4.2%
|
9,39
|
48 884
USD
|
|
2019-09-20 |
2019-09-19 |
V
Vente
|
HOLLER FRANK A
|
7 600
-5.8%
9,27
70 452
USD
|
7 600
-5.8%
|
9,27
|
70 452
USD
|
|
2019-09-18 |
2019-09-18 |
V
Vente
|
HOLLER FRANK A
|
4 368
-3.2%
9,28
40 535
USD
|
4 368
-3.2%
|
9,28
|
40 535
USD
|
|
2019-09-18 |
2019-09-17 |
V
Vente
|
HOLLER FRANK A
|
5 069
-3.6%
9,32
47 243
USD
|
5 069
-3.6%
|
9,32
|
47 243
USD
|
|
2019-09-17 |
2019-09-13 |
V
Vente
|
AZAB MOHAMMAD
|
23
-0.0%
9,31
214
USD
|
23
-0.0%
|
9,31
|
214
USD
|
|
2017-11-16 |
2017-11-15 |
A
Achat
|
AZAB MOHAMMAD
|
15 000
+51.4%
2,22
33 281
USD
|
15 000
+51.4%
|
2,22
|
33 281
USD
|
|
2017-09-25 |
2017-09-22 |
A
Achat
|
AZAB MOHAMMAD
|
8 000
+37.7%
2,95
23 600
USD
|
8 000
+37.7%
|
2,95
|
23 600
USD
|
|
2017-09-25 |
2017-09-21 |
A
Achat
|
AZAB MOHAMMAD
|
2 000
+10.4%
2,95
5 900
USD
|
2 000
+10.4%
|
2,95
|
5 900
USD
|
|
2017-08-21 |
2017-08-18 |
A
Achat
|
WINQUIST RAYMOND
Head, Translational Research
|
1 000
+inf%
3,00
2 995
USD
|
1 000
+inf%
|
3,00
|
2 995
USD
|
|
2017-08-21 |
2017-08-18 |
A
Achat
|
AZAB MOHAMMAD
|
6 312
+48.9%
2,90
18 302
USD
|
6 312
+48.9%
|
2,90
|
18 302
USD
|
|
2017-08-21 |
2017-08-17 |
A
Achat
|
AZAB MOHAMMAD
|
23
+0.2%
2,65
61
USD
|
23
+0.2%
|
2,65
|
61
USD
|
|
2017-08-17 |
2017-08-15 |
A
Achat
|
EMPFIELD JAMES R.
SVP, Drug Discovery
|
10 000
+inf%
2,48
24 824
USD
|
10 000
+inf%
|
2,48
|
24 824
USD
|
|
2017-08-16 |
2017-08-15 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
7 429
+0.7%
2,41
17 920
USD
|
7 429
+0.7%
|
2,41
|
17 920
USD
|
|
2017-08-16 |
2017-08-15 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
11 429
+0.7%
2,41
27 569
USD
|
11 429
+0.7%
|
2,41
|
27 569
USD
|
|
2017-08-16 |
2017-08-14 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
13 337
+1.3%
2,70
36 058
USD
|
13 337
+1.3%
|
2,70
|
36 058
USD
|
|
2017-08-16 |
2017-08-14 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
28 007
+1.7%
2,70
75 720
USD
|
28 007
+1.7%
|
2,70
|
75 720
USD
|
|
2017-08-15 |
2017-08-14 |
A
Achat
|
Svoronos Dawn
|
50 000
+inf%
2,82
140 770
USD
|
50 000
+inf%
|
2,82
|
140 770
USD
|
|
2017-08-14 |
2017-08-14 |
A
Achat
|
Hayden Michael R
|
15 000
+10.3%
2,75
41 247
USD
|
15 000
+10.3%
|
2,75
|
41 247
USD
|
|
2017-08-14 |
2017-08-11 |
A
Achat
|
GANNON STEVEN
|
15 000
+inf%
2,82
42 267
USD
|
15 000
+inf%
|
2,82
|
42 267
USD
|
|
2017-08-14 |
2017-08-10 |
A
Achat
|
MORTIMER IAN
CFO & COO
|
10 000
+232.6%
2,90
29 000
USD
|
10 000
+232.6%
|
2,90
|
29 000
USD
|
|
2017-08-14 |
2017-08-10 |
A
Achat
|
MORTIMER IAN
CFO & COO
|
5 000
+500.0%
2,85
14 225
USD
|
5 000
+500.0%
|
2,85
|
14 225
USD
|
|
2017-08-14 |
2017-08-10 |
A
Achat
|
SCHELLER RICHARD H
|
7 000
+inf%
2,85
19 950
USD
|
7 000
+inf%
|
2,85
|
19 950
USD
|
|
2017-08-14 |
2017-08-10 |
A
Achat
|
PATOU GARY
|
7 500
+150.0%
2,78
20 836
USD
|
7 500
+150.0%
|
2,78
|
20 836
USD
|
|
2017-08-14 |
2017-08-10 |
A
Achat
|
PIMSTONE SIMON N.
President & CEO
Administrateur exécutif
|
6 000
+2.8%
2,90
17 400
USD
|
6 000
+2.8%
|
2,90
|
17 400
USD
|
|
2017-08-10 |
2017-08-08 |
A
Achat
|
PATOU GARY
|
5 000
+inf%
3,00
15 003
USD
|
5 000
+inf%
|
3,00
|
15 003
USD
|
|
2017-06-29 |
2017-06-27 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
8 496
+2.9%
4,00
33 984
USD
|
8 496
+2.9%
|
4,00
|
33 984
USD
|
|
2017-06-29 |
2017-06-27 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
30 170
+2.9%
4,00
120 680
USD
|
30 170
+2.9%
|
4,00
|
120 680
USD
|
|
2017-06-29 |
2017-06-27 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
46 795
+2.9%
4,00
187 180
USD
|
46 795
+2.9%
|
4,00
|
187 180
USD
|
|
2017-06-23 |
2017-06-22 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
854
+0.3%
4,00
3 416
USD
|
854
+0.3%
|
4,00
|
3 416
USD
|
|
2017-06-23 |
2017-06-22 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
2 884
+0.3%
4,00
11 536
USD
|
2 884
+0.3%
|
4,00
|
11 536
USD
|
|
2017-06-23 |
2017-06-22 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
4 525
+0.3%
4,00
18 100
USD
|
4 525
+0.3%
|
4,00
|
18 100
USD
|
|
2017-06-23 |
2017-06-21 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
1 362
+0.5%
4,00
5 448
USD
|
1 362
+0.5%
|
4,00
|
5 448
USD
|
|
2017-06-23 |
2017-06-21 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
4 406
+0.4%
4,00
17 624
USD
|
4 406
+0.4%
|
4,00
|
17 624
USD
|
|
2017-06-23 |
2017-06-21 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
6 380
+0.4%
4,00
25 520
USD
|
6 380
+0.4%
|
4,00
|
25 520
USD
|
|
2017-06-19 |
2017-06-19 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
357
+0.1%
3,85
1 374
USD
|
357
+0.1%
|
3,85
|
1 374
USD
|
|
2017-06-19 |
2017-06-19 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
1 271
+0.1%
3,85
4 893
USD
|
1 271
+0.1%
|
3,85
|
4 893
USD
|
|
2017-06-19 |
2017-06-19 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
1 967
+0.1%
3,85
7 573
USD
|
1 967
+0.1%
|
3,85
|
7 573
USD
|
|
2017-06-19 |
2017-06-16 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
1 064
+0.4%
3,85
4 096
USD
|
1 064
+0.4%
|
3,85
|
4 096
USD
|
|
2017-06-19 |
2017-06-16 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
3 873
+0.4%
3,85
14 911
USD
|
3 873
+0.4%
|
3,85
|
14 911
USD
|
|
2017-06-19 |
2017-06-16 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
6 097
+0.4%
3,85
23 473
USD
|
6 097
+0.4%
|
3,85
|
23 473
USD
|
|
2017-06-19 |
2017-06-15 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
1 160
+0.4%
3,84
4 451
USD
|
1 160
+0.4%
|
3,84
|
4 451
USD
|
|
2017-06-19 |
2017-06-15 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
3 845
+0.4%
3,84
14 753
USD
|
3 845
+0.4%
|
3,84
|
14 753
USD
|
|
2017-06-19 |
2017-06-15 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
6 774
+0.4%
3,84
25 992
USD
|
6 774
+0.4%
|
3,84
|
25 992
USD
|
|
2017-06-08 |
2017-06-07 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
20 594
+7.8%
3,85
79 312
USD
|
20 594
+7.8%
|
3,85
|
79 312
USD
|
|
2017-06-08 |
2017-06-07 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
73 749
+7.9%
3,85
284 022
USD
|
73 749
+7.9%
|
3,85
|
284 022
USD
|
|
2017-06-08 |
2017-06-07 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
113 446
+7.8%
3,85
436 903
USD
|
113 446
+7.8%
|
3,85
|
436 903
USD
|
|
2017-06-08 |
2017-06-06 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
913
+0.3%
3,75
3 424
USD
|
913
+0.3%
|
3,75
|
3 424
USD
|
|
2017-06-08 |
2017-06-06 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
53 260
+6.0%
3,75
199 725
USD
|
53 260
+6.0%
|
3,75
|
199 725
USD
|
|
2017-06-08 |
2017-06-06 |
A
Achat
|
BVF PARTNERS L P/IL
Actionnaire important
|
96 736
+7.2%
3,75
362 760
USD
|
96 736
+7.2%
|
3,75
|
362 760
USD
|
|
2016-12-19 |
2016-12-15 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
30 000
-20.6%
7,85
235 500
USD
|
30 000
-20.6%
|
7,85
|
235 500
USD
|
|
2016-08-23 |
2016-08-19 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
11 938
-7.6%
7,65
91 338
USD
|
11 938
-7.6%
|
7,65
|
91 338
USD
|
|
2016-08-18 |
2016-08-18 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
9 599
-5.7%
7,70
73 912
USD
|
9 599
-5.7%
|
7,70
|
73 912
USD
|
|
2016-08-18 |
2016-08-17 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
1 600
-0.9%
7,89
12 624
USD
|
1 600
-0.9%
|
7,89
|
12 624
USD
|
|
2016-08-18 |
2016-08-16 |
V
Vente
|
HOLLER FRANK A
Administrateur non-exécutif
|
6 863
-3.9%
8,25
56 620
USD
|
6 863
-3.9%
|
8,25
|
56 620
USD
|
|
2016-06-28 |
2016-06-24 |
A
Achat
|
MORTIMER IAN
CFO & COO
Dirigeant
|
1 300
+43.3%
6,30
8 190
USD
|
1 300
+43.3%
|
6,30
|
8 190
USD
|
|
2016-06-28 |
2016-06-24 |
A
Achat
|
MORTIMER IAN
CFO & COO
Dirigeant
|
2 000
+200.0%
6,25
12 500
USD
|
2 000
+200.0%
|
6,25
|
12 500
USD
|
|
2016-06-28 |
2016-06-24 |
A
Achat
|
MORTIMER IAN
CFO & COO
Dirigeant
|
1 000
+inf%
6,10
6 100
USD
|
1 000
+inf%
|
6,10
|
6 100
USD
|
|
2016-06-28 |
2016-06-24 |
A
Achat
|
MORTIMER IAN
CFO & COO
Dirigeant
|
1 000
+inf%
6,15
6 150
USD
|
1 000
+inf%
|
6,15
|
6 150
USD
|
|
2015-09-24 |
2015-09-24 |
V
Vente
|
GOLDBERG Y. PAUL
VP of Clinical Development
Dirigeant
|
12 000
-66.7%
8,60
103 200
USD
|
12 000
-66.7%
|
8,60
|
103 200
USD
|
|
2015-09-24 |
2015-09-23 |
V
Vente
|
GOLDBERG Y. PAUL
VP of Clinical Development
Dirigeant
|
4 000
-18.2%
9,02
36 080
USD
|
4 000
-18.2%
|
9,02
|
36 080
USD
|
|
2015-09-24 |
2015-09-22 |
V
Vente
|
GOLDBERG Y. PAUL
VP of Clinical Development
Dirigeant
|
6 149
-21.8%
9,33
57 384
USD
|
6 149
-21.8%
|
9,33
|
57 384
USD
|
|